Accounts Payable - Zhejiang Ausun Pharmaceutical Co Ltd (SSE:603229) - Alpha Spread

Zhejiang Ausun Pharmaceutical Co Ltd
SSE:603229

Watchlist Manager
Zhejiang Ausun Pharmaceutical Co Ltd Logo
Zhejiang Ausun Pharmaceutical Co Ltd
SSE:603229
Watchlist
Price: 6.59 CNY -2.37% Market Closed
Market Cap: 5.5B CNY
Have any thoughts about
Zhejiang Ausun Pharmaceutical Co Ltd?
Write Note

Zhejiang Ausun Pharmaceutical Co Ltd
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Zhejiang Ausun Pharmaceutical Co Ltd
Accounts Payable Peer Comparison

Comparables:
H
3692
600436
600276
000538
S
688506

Competitive Accounts Payable Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Zhejiang Ausun Pharmaceutical Co Ltd
SSE:603229
Accounts Payable
ÂĄ250.2m
CAGR 3-Years
18%
CAGR 5-Years
27%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Accounts Payable
ÂĄ163.8m
CAGR 3-Years
10%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Accounts Payable
ÂĄ470.9m
CAGR 3-Years
19%
CAGR 5-Years
16%
CAGR 10-Years
20%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Accounts Payable
ÂĄ1.4B
CAGR 3-Years
9%
CAGR 5-Years
0%
CAGR 10-Years
17%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Accounts Payable
ÂĄ4.5B
CAGR 3-Years
3%
CAGR 5-Years
0%
CAGR 10-Years
8%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Accounts Payable
ÂĄ307.9m
CAGR 3-Years
65%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Zhejiang Ausun Pharmaceutical Co Ltd's Accounts Payable?
Accounts Payable
250.2m CNY

Based on the financial report for Jun 30, 2024, Zhejiang Ausun Pharmaceutical Co Ltd's Accounts Payable amounts to 250.2m CNY.

What is Zhejiang Ausun Pharmaceutical Co Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
27%

Over the last year, the Accounts Payable growth was -11%. The average annual Accounts Payable growth rates for Zhejiang Ausun Pharmaceutical Co Ltd have been 18% over the past three years , 27% over the past five years .

Back to Top